PRA-216 for Moderate to Severe Atopic Dermatitis
Tests PRA-216 against a placebo in adults with moderate to severe atopic dermatitis.
Plain-language title generated from the registry record
Registry title: PRA-216 Atopic Dermatitis Safety and Efficacy Study
Key facts
- Where
- Auckland, Christchurch, and Hamilton, New ZealandSee the 4 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07810777, who can take part
Where in New Zealand
- Aotearoa Clinical TrialsAuckland, New ZealandTaking people
- Optimal Clinical Trials (North)Auckland, New ZealandTaking people
- Momentum ChristchurchChristchurch, New ZealandTaking people
- Clinical Trials New ZealandHamilton, New ZealandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Prana Therapies Inc
- Trial code
- NCT07810777
- Record updated
- 28 October 2026
- Original description
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)Read full original descriptionShow less
A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Moderate to Severe Atopic Dermatitis
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
Inclusion: Must be in good health with no significant medical history; Willing and able to attend all study visits, comply with study requirements; Able and willing to provide written informed consent; Documented AD diagnosis prior to enrollment; History of inadequate response to topical medications for AD.
Exclusion: Known history of illicit drug use or alcoholism within 12 months prior to the first dose of study agent; Receipt of antibody therapy within 4 months or 5 half-lives; Other investigational agent(s) within 30 days or 5 half-lives; Evidence of clinically significant skin condition or disease other than AD; Any physical or psychological condition that prohibits study completion; History of severe allergic reactions or hypersensitivity.